Hepatocellular carcinoma in Australia 1982 to 2014: increasing incidence and improving survival.

08:00 EDT 19th September 2018 | BioPortfolio

Summary of "Hepatocellular carcinoma in Australia 1982 to 2014: increasing incidence and improving survival."

There is a paucity of accurate and current data on HCC trends in incidence and survival in developed countries. We performed an Australia-wide assessment of HCC epidemiology across a 33-year time span aiming to accurately describe changes in incidence and survival
Cases of HCC from 1982 to 2014 were identified via the Australian Cancer Database (ACD). Trends in incidence rates were explored using piecewise linear regression. Survival was compared by Kaplan-Meier survival curves and 1-, 3- and 5-year survival probabilities by year of diagnosis
Age-adjusted HCC incidence rate increased from 1.38 per 100,000 (95%
1.34-1.43) in 1982 to 4.96 per 100,000 (95%
4.89-5.03, p<0.001) in 2014 with an average annual percentage increase of 4.46% (95%
4.24%-4.69%). The highest incidence rate in 2014 was in those aged 75-79 (24.31 per 100,000; 95%
19.50-29.12). Almost 80% of cases across the period were men who had significantly higher age-adjusted incidence rates in 2014 than women (8.55 per 100,000 {95%
8.42-8.68} versus 1.65 per 100,000 {95%
1.60-1.70}; p<0.001). A hepatitis C (HCV) birth cohort effect was identified and associated with rapid increases in HCC incidence when members of the cohort aged and entered into age groups 45-49, 50-54 and 55-59. Median survival increased from 2.10 months (95%
1.57-2.62 months) in those diagnosed between 1982-1984 to 12.07 months (95%
11.17-12.97 months) when diagnosed between 2010-2014 (p<0.001)
An Australia-wide analysis of HCC epidemiological trends across three decades shows significant and consistent increases in both incidence and survival.


Journal Details

This article was published in the following journal.

Name: Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231


DeepDyve research library

PubMed Articles [9043 Associated PubMed Articles listed on BioPortfolio]

When Soluble Fibers Meet Hepatocellular Carcinoma: The Dark Side of Fermentation.

Fermentation of dietary soluble fibers by our gut microbiota generates short-chain fatty acids (SCFAs) and metabolites, upholding health and being a valuable food supplement. Recently, in Cell, Singh...

Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.

The main objective of this study was to develop novel BSA nanoparticles (BSA NPs) for improving the bioavailability of curcumin as an anticancer drug, and those BSA NPs were galactosylated for forming...

Preoperative Alfa-Fetoprotein and Fibrinogen Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Regardless of the Milan Criteria: Model Development with External Validation.

Patient selection is critically important in improving the outcomes of liver transplantation for hepatocellular carcinoma. The aim of the current study was to identify biochemical measures that could ...

FDG PET/CT Imaging of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus.

Hepatocellular carcinoma rarely involves the major bile duct. Here, we reported a 46-year-old man with liver cancer who underwent FDG PET/CT for staging. The images showed abnormal FDG uptake in the l...

Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion.

Linc-POU3F3 showed an up-regulated tendency and functioned as tumor promoter in glioma, esophageal cancer and colorectal cancer. There was no report about the expression pattern and clinical value of ...

Clinical Trials [6017 Associated Clinical Trials listed on BioPortfolio]

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Hepatocellular carcinoma is one the leading cause of increasing cancer-specific mortality worldwide. Early diagnosis of hepatocellular carcinoma provides opportunity for curative therapeut...

Hepatocellular Carcinoma Registry in Asia

This registry is designed as a multi-centre longitudinal cohort study of patients diagnosed with HCC between 1st January 2013 and 30th June 2018 in nine countries (ie, Korea, Taiwan, Thail...

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard tre...

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dos...

Medical and Biotech [MESH] Definitions

An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.

The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.

The first alpha-globulins to appear in mammalian sera during development of the embryo and the dominant serum proteins in early embryonic life. They reappear in the adult serum during certain pathologic states, primarily hepatocellular carcinoma. They may also be elevated in the amniotic fluid and maternal serum during pregnancy in ANENCEPHALY.

A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.

Quick Search


DeepDyve research library

Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Searches Linking to this Article